Autocrine human growth hormone reduces mammary and endometrial carcinoma cell sensitivity to mitomycin C

Oncology Reports

Volumn 26, Issue 2, 2011, Pages 487-493

  Bougen, Nicola M ^a   Yang, Teresa ^a   Chen, Helen ^a   Lobie, Peter E ^b   Perry, Jo K ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Chemotherapy; Drug resistance; Endometrial carcinoma; Growth hormone; Mammary carcinoma; Mitomycin C

Indexed keywords

DNA; HUMAN GROWTH HORMONE; MATRIGEL; MITOMYCIN C; RNA;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROTECTION; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CELL STRAIN T47D; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG SENSITIVITY; ENDOMETRIUM CARCINOMA; GENE EXPRESSION; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN GROWTH HORMONE GENE; IN VITRO STUDY; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DRUG RESISTANCE; ENDOMETRIAL NEOPLASMS; FEMALE; GENE THERAPY; HUMAN GROWTH HORMONE; HUMANS; MITOMYCIN; TRANSFECTION;

EID: 79958227910     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1305     Document Type: Article

References (44)

1. Tomasz M: Mitomycin C: small, fast and deadly (but very selective). Curr Biol 2: 575-579, 1995.
2. Dronkert ML and Kanaar R: Repair of DNA interstrand cross-links. Mutat Res 486: 217-247, 2001.
3. Mao Y, Varoglu M and Sherman DH: Molecular characterisation and analysis of the biosynthetic gene cluster for the antitumor antibiotic mitomycin C from Streptomyces lavendulae NRRL 2564. Chem Biol 6: 251-263, 1999.
4. Spanswick VJ, Cummings J and Smyth JF: Current issues in the enzymology of mitomycin C activation. Gen Pharmacol 31: 539-544, 1998.
5. Sartorelli AC and Rockwell S: Mitomycin C: a prototype bioreductive agent. Oncol Res 6: 501-508, 1994.
6. Rothfuss A and Grompe M: Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway. Mol Cell Biol 24: 123-134, 2004.
7. Niedernhofer LJ, Odijk H, Budzowska M, et al: The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24: 5776-5787, 2004.
8. Tomasz M and Palom Y: The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther 76: 73-87, 1997.
9. Bradner WT: Mitomycin C: a clinical update. Cancer Treat Rev 27: 35-50, 2001.
10. Henderson IC: Recent advances in the usage of mitomycin. Oncology 50 (Suppl 1): 1-83, 1993.
11. Scheithauer W, Kornek G, Haider K, et al: Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C. Breast Cancer Res Treat 26: 49-53, 1993.
12. Garewal HS, Brooks RJ, Jones SE and Miller TP: Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine. J Clin Oncol 1: 772-775, 1983.
13. Pouillart R, Huong TH, Brugerie E and Lheritier J: Sequential administration of two oncostatic drugs: study of modalities for pharmacodynamic potentiation. Biomedicine 21: 471-479, 1974.
14. Sulkes A, Gez E, Pfeffer MR, Catane R, Isacson R and Biran S: Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol 18: 162-167, 1986.
15. Xu Y and Shapiro CL: Rationale for mitomycin and irinotecan use in advanced breast cancer. Oncology 17: 25-28, 2003.
16. Mrozek E, Kolesar J, Young D, Allen J, Villalona-Calero M and Shapiro CL: Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). Ann Oncol 19: 1417-1422, 2008.
17. Perry JK, Mohankumar KM, Emerald BS, Mertani HC and Lobie PE: The contribution of growth hormone to mammary neoplasia. J Mammary Gland Biol Neoplasia 13: 131-145, 2008.
18. Zhu T, Starling-Emerald B, Zhang X, et al: Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res 65: 317-324, 2005.
19. Kaulsay KK, Mertani HC, Tornell J, Morel G, Lee KO and Lobie PE: Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone. Exp Cell Res 250: 35-50, 1999.
20. Mukhina S, Liu D, Guo K, et al: Autocrine growth hormone prevents lactogenic differentiation of mouse mammary epithelial cells. Endocrinology 147: 1819-1829, 2006.
21. Pandey V, Perry JK, Mohankumar KM, et al: Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology 149: 3909-3919, 2008.
22. Perry JK, Emerald BS, Mertani HC and Lobie PE: The oncogenic potential of growth hormone. Growth Horm IGF Res 16: 277-289, 2006.
23. Goh EL, Pircher TJ and Lobie PE: Growth hormone promotion of tubulin polymerization stabilizes the microtubule network and protects against colchicine-induced apoptosis. Endocrinology 139: 4364-4372, 1998.
24. Mojarrad M, Momeny M, Mansuri F, et al: Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen. Med Oncol 27: 474-480, 2010.
25. Zatelli MC, Minoia M, Mole D, et al: Growth hormone excess promotes breast cancer chemoresistance. J Clin Endocrinol Metab 94: 3931-3938, 2009.
26. Brunet-Dunand SE, Vouyovitch C, Araneda S, et al: Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. Endocrinology 150: 1341-1352, 2009.
27. Mertani HC, Zhu T, Goh EL, Lee KO, Morel G and Lobie PE: Autocrine human growth hormone (hGH) regulation of human mammary carcinoma cell gene expression. Identification of CHOP as a mediator of hGH-stimulated human mammary carcinoma cell survival. J Biol Chem 276: 21464-21475, 2001.
28. Kaulsay KK, Zhu T, Bennett W, Lee KO and Lobie PE: The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology 142: 767-777, 2001.
29. Amiry N, Kong X, Muniraj N, et al: Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells. Endocrinology 150: 4473-4483, 2009.
30. Olive PL and Banath JP: The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 1: 23-29, 2006.
31. Kopchick JJ, Parkinson C, Stevens EC and Trainer PJ: Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23: 623-646, 2002.
32. van der Lely AJ and Kopchick JJ: Growth hormone receptor antagonists. Neuroendocrinology 83: 264-268, 2006.
33. Gatti L and Zunino F: Overview of tumor cell chemoresistance mechanisms. Methods Mol Med 111: 127-148, 2005.
34. Coley HM: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 34: 378-390, 2008.
35. Luqmani YA: Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14 (Suppl 1): 35-48, 2005.
36. Martinez-Lacaci I, Garcia Morales P, Soto JL and Saceda M: Tumour cell resistance in cancer therapy. Clin Transl Oncol 9: 13-20, 2007.
37. Sekine I, Sasaki Y, Fujii H, et al: Recurrent breast cancer treated successfully with mitomycin-C and vinblastine after failure of both doxorubicin-containing regimen and paclitaxel - a case report. Tohoku J Exp Med 178: 331-337, 1996.
38. Legha SS: A review of mitomycin regimens in advanced breast cancer therapy. Clin Ther 7: 286-307, 1985.
39. Pasterz RB, Buzdar AU, Hortobagyi GN and Blumenschein GR: Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. Cancer 56: 2381-2384, 1985.
40. Garewal HS: Mitomycin C in the chemotherapy of advanced breast cancer. Semin Oncol 15: 74-79, 1988.
41. Yusa K, Sato W, Yamazaki A, Tsukahara S and Tsuruo T: Cross-resistance of human multidrug-resistant cells to mitomycin C. Anticancer Res 11: 1301-1304, 1991.
42. Zhu Z, Mukhina S, Zhu T, Mertani HC, Lee K-O and Lobie PE: p44/42 MAP kinase-dependent regulation of catalase by autocrine human growth hormone protects human mammary carcinoma cells from oxidative stress-induced apoptosis. Oncogene 24: 3774-3785, 2005.
43. Funakoshi T, Yanai A, Shinoda K, Kawano MM and Mizukami Y: G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem Biophys Res Commun 346: 904-910, 2006.
44. Vivacqua A, Bonofiglio D, Recchia AG, et al: The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20: 631-646, 2006.